Targeting the (Un)differentiated State of Cancer

Lajos V Kemeny; David E Fisher

doi:10.1016/j.ccell.2018.04.007

Targeting the (Un)differentiated State of Cancer

Cancer Cell. 2018 May 14;33(5):793-795. doi: 10.1016/j.ccell.2018.04.007.

Authors

Lajos V Kemeny¹, David E Fisher²

Affiliations

¹ Cutaneous Biology Research Center, Department of Dermatology and Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
² Cutaneous Biology Research Center, Department of Dermatology and Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: dfisher3@partners.org.

PMID: 29763619
DOI: 10.1016/j.ccell.2018.04.007

Abstract

Dedifferentation in cancer is associated with intrinsic and acquired resistance to therapies. In this issue of Cancer Cell, Tsoi et al. identify four differentiation states in melanoma and provide evidence that melanoma cells develop drug resistance through a stepwise dedifferentiation process, making them vulnerable to ferroptotic cell death-inducing compounds.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Cell Differentiation
Cell Line, Tumor
Humans
Iron*
Melanoma*
Oxidative Stress

Substances

Iron

Abstract

Publication types

MeSH terms

Substances

Grants and funding